Europe Lung Cancer Therapeutics Market Growth, Size, Trends, Share, Revenue and Future Outlook
Europe Lung Cancer Therapeutics Market Size- By Cancer Type, By Molecule Type, By Treatment Type, By Therapy Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Apr-2024 | Report ID: HLCA2446 | Pages: 1 - 155 | Formats*: |
| Category : Healthcare | |||
Europe Lung Cancer Therapeutics Market Introduction and Overview
According to SPER Market Research, the Europe Lung Cancer Therapeutics Market is estimated to reach USD 4.05 Billion by 2033 with a CAGR of 7.3%.
The report includes an in-depth analysis of the Europe Lung Cancer Therapeutics Market, including market size and trends, product mix, applications, and supplier analysis. Lung cancer is a form of cancer that impairs the ability of the lungs to supply oxygen to the blood. It is one of the most frequent types of cancer, with a significant fatality rate. Lung cancer is defined as the uncontrolled development of cells in the lungs. The leading causes of lung cancer include cigarette smoking, asbestos exposure, and smoking cigars. This illness is distinguished by weight loss, shortness of breath, cough, and chest pain. Lung cancer is also known as lung carcinoma.
Market Opportunities and Challenges
The rising prevalence of lung cancer and growing need for tailored therapies, as well as the availability of highly effective medications, are the primary factors influencing the growth of the lung cancer therapeutics market. Furthermore, environmental pollution, smoking, reimbursements, and an increase in health insurance premiums are the factors that will accelerate the market's growth rate. Furthermore, the increased use of early detection and the growing elderly population will moderate the growth rate of the lung cancer therapies market.
Furthermore, increased R&D activities, the launch of nanomedicines for the treatment of lung cancer, and rising approvals in lung cancer therapies will all contribute to market expansion. However, the availability of generic medications, the high cost of treatment, and the side effects associated with radiation and chemotherapy all operate as market limitations, impeding market expansion. Poor cancer diagnostic facilities and a shortage of competent personnel will exacerbate the lung cancer therapies industry.
Market Competitive Landscape
The lung cancer therapies industry is extremely competitive, with numerous pharmaceutical companies fighting for market share. Multinational corporations and smaller oncology-focused biotechnology enterprises are among the market's key players. These companies prioritise research and development in order to bring novel cures to market. Strategic collaborations, mergers, and acquisitions are frequent methods used by market participants to extend their product line and global reach. The major key players in the Europe Lung Cancer Therapeutics Market are: Allergan, Amgen Inc, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck Sharp & Dohme Corp, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Cancer Type, By Molecule Type, By Treatment Type, By Therapy Type, By End User |
| Regions covered | Belgium, France, Germany, Italy, Netherlands, Russia, Spain, Switzerland, The U.K., Turkey, Rest of Europe |
| Companies Covered | Allergan, Amgen Inc, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck Sharp & Dohme Corp, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Others. |
COVID-19 Impact on Europe Lung Cancer Therapeutics Market
The COVID-19 pandemic has had a substantial influence on the European lung cancer medicines industry. Delays in detection and treatment owing to reallocation of healthcare resources and patient unwillingness to seek medical care have resulted in fewer lung cancer diagnoses and subsequent treatment initiations. Furthermore, disruptions in drug manufacturing and supply chains have hampered the availability of lung cancer treatments. Clinical studies for new therapies have also been halted, limiting the development of revolutionary treatments. However, telemedicine acceptance has expanded, allowing for remote patient consultations and monitoring. Despite these obstacles, attempts to resume routine healthcare services and intensify immunisation campaigns are expected to slowly restore market stability.
Key Target Audience:
- Pharmaceutical Companies
- Biotechnology Companies
- Medical Device Manufacturers
- Research Institutions
- Academic Institutions
- Healthcare Providers
- Regulatory Authorities
- Patients and Patient Advocacy Groups
- Investors and Financial Institutions
- Others
Our in-depth analysis of the Europe Lung Cancer Therapeutics Market includes the following segments:
| By Cancer Type: |
|
| By Molecule Type: |
|
| By Treatment Type: |
|
| By Therapy Type: |
|
| By End User: |
|
Key Topics Covered in the Report:
- Europe Lung Cancer Therapeutics Market Size (FY’2024-FY’2033)
- Overview of Europe Lung Cancer Therapeutics Market
- Segmentation of Europe Lung Cancer Therapeutics Market By Cancer Type (Chest Wall Tumors, Mediastinal Tumors, Mesothelioma, Metastatic Lung Cancer, Non-Small Cell Lung Cancer, Pulmonary Neuroendocrine Tumors)
- Segmentation of Europe Lung Cancer Therapeutics Market By Molecule Type (Biologics, Small Molecules)
- Segmentation of Europe Lung Cancer Therapeutics Market By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Others)
- Segmentation of Europe Lung Cancer Therapeutics Market By Therapy Type (Combination Therapy, Single Drug Therapy)
- Segmentation of Europe Lung Cancer Therapeutics Market By End User (Homecare, Hospitals, Speciality Clinics, Others)
- Statistical Snap of Europe Lung Cancer Therapeutics Market
- Expansion Analysis of Europe Lung Cancer Therapeutics Market
- Problems and Obstacles in Europe Lung Cancer Therapeutics Market
- Competitive Landscape in the Europe Lung Cancer Therapeutics Market
- Impact of COVID-19 and Demonetization on Europe Lung Cancer Therapeutics Market
- Details on Current Investment in Europe Lung Cancer Therapeutics Market
- Competitive Analysis of Europe Lung Cancer Therapeutics Market
- Prominent Players in the Europe Lung Cancer Therapeutics Market
- SWOT Analysis of Europe Lung Cancer Therapeutics Market
- Europe Lung Cancer Therapeutics Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Europe Lung Cancer Therapeutics Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Lung Cancer Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Lung Cancer Therapeutics Market
7. Europe Lung Cancer Therapeutics Market, By Cancer Type (USD Million) 2020-2033
7.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Cancer Type, 2020-20267.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Cancer Type, 2027-20337.3. Chest Wall Tumors7.4. Mediastinal Tumors7.5. Mesothelioma7.6. Metastatic Lung Cancer7.7. Non-Small Cell Lung Cancer7.8. Pulmonary Neuroendocrine Tumors
8. Europe Lung Cancer Therapeutics Market, By Molecule Type (USD Million) 2020-2033
8.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Molecule Type, 2020-20268.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Molecule Type, 2027-20338.3. Biologics8.4. Small Molecules
9. Europe Lung Cancer Therapeutics Market, By Treatment Type (USD Million) 2020-2033
9.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Treatment Type, 2020-20269.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Treatment Type, 2027-20339.3. Chemotherapy9.4. Immunotherapy9.5. Radiation Therapy9.6. Targeted Therapy9.7. Others
10. Europe Lung Cancer Therapeutics Market, By Therapy Type (USD Million) 2020-2033
10.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Therapy Type, 2020-202610.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Therapy Type, 2027-203310.3. Combination Therapy10.4. Single Drug Therapy
11. Europe Lung Cancer Therapeutics Market, By End User (USD Million) 2020-2033
11.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By End User, 2020-202611.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By End User, 2027-203311.3. Homecare11.4. Hospitals11.5. Speciality Clinics11.6. Others
12. Europe Lung Cancer Therapeutics Market Forecast, 2020-2033 (USD Million)
12.1. Europe Lung Cancer Therapeutics Market Size and Market Share
13. Europe Lung Cancer Therapeutics Market, By Region, 2020-2033 (USD Million)
13.1. Europe Lung Cancer Therapeutics Market Size and Market Share By Region (2020-2026)13.2. Europe Lung Cancer Therapeutics Market Size and Market Share By Region (2027-2033)13.3. Belgium13.4. France13.5. Germany13.6. Italy13.7. Netherlands13.8. Russia13.9. Spain13.10. Switzerland13.11. The U.K.13.12. Turkey13.13. Rest of Europe
14. Company Profile
14.1. Allergan14.1.1. Company details14.1.2. Financial outlook14.1.3. Product summary14.1.4. Recent developments14.2. Amgen Inc14.2.1. Company details14.2.2. Financial outlook14.2.3. Product summary14.2.4. Recent developments14.3. Dr. Reddy’s Laboratories Ltd14.3.1. Company details14.3.2. Financial outlook14.3.3. Product summary14.3.4. Recent developments14.4. GlaxoSmithKline plc14.4.1. Company details14.4.2. Financial outlook14.4.3. Product summary14.4.4. Recent developments14.5. Johnson & Johnson Private Limited14.5.1. Company details14.5.2. Financial outlook14.5.3. Product summary14.5.4. Recent developments14.6. Merck Sharp & Dohme Corp14.6.1. Company details14.6.2. Financial outlook14.6.3. Product summary14.6.4. Recent developments14.7. Novartis AG14.7.1. Company details14.7.2. Financial outlook14.7.3. Product summary14.7.4. Recent developments14.8. Pfizer Inc14.8.1. Company details14.8.2. Financial outlook14.8.3. Product summary14.8.4. Recent developments14.9. Sun Pharmaceutical Industries Ltd14.9.1. Company details14.9.2. Financial outlook14.9.3. Product summary14.9.4. Recent developments14.10. Takeda Pharmaceutical Company Limited14.10.1. Company details14.10.2. Financial outlook14.10.3. Product summary14.10.4. Recent developments14.11. Teva Pharmaceutical Industries Ltd.14.11.1. Company details14.11.2. Financial outlook14.11.3. Product summary14.11.4. Recent developments14.12. Others
15. List of Abbreviations
16. Reference Links
17. Conclusion
18. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Europe Lung Cancer Therapeutics Market is projected to reach USD 4.05 billion by 2033, growing at a CAGR of 7.3% during the forecast period.
Europe Lung Cancer Therapeutics Market grew in Market size from 2022. The Market is expected to reach USD 4.05 billion by 2033, at a CAGR of 7.3% during the forecast period.
Europe Lung Cancer Therapeutics Market CAGR of 7.3% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Europe Lung Cancer Therapeutics Market size is USD 4.05 billion from 2024 to 2033.
Europe Lung Cancer Therapeutics Market Segment is covered By Cancer Type, By Molecule Type, By Treatment Type, By Therapy Type, By End User.
The Europe is anticipated to have the highest Market share in the Europe Lung Cancer Therapeutics Market.
The key players in the Market include Companies Covered Allergan, Amgen Inc, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck Sharp & Dohme Corp, Teva Pharmaceutical Industries Ltd., Others.
It is one of the most frequent types of cancer, with a significant fatality rate. Lung cancer is defined as the uncontrolled development of cells in the lungs.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
